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Background: The current study sought to compare 28-day mortality rates in cancer patients with febrile neutropenia
(FN) and gastrointestinal (GI) symptoms who underwent monotherapy using an antibiotic with antipseudomonal and
anti-anaerobic activity (piperacillin-tazobactam or a carbapenem) and a group treated with a combination of
cefepime-metronidazole.
Findings: We performed a prospective cohort study in a single tertiary hospital from October 2009 to August 2011. All
consecutive adult cancer patients admitted with FN secondary to intensive chemotherapy and GI symptoms (abdominal
pain, diarrhea or perianal pain) were evaluated. Kaplan-Meier curves were used for calculating time-dependent
occurence of death. In total, 37 patients with FN and GI symptoms were evaluated (15 in monotherapy arm and 22 in
the combination therapy arm). Treatment with combination cefepime and metronidazole resulted in a lower 28-day
mortality rate compared with piperacillin-tazobactam or carbapenem monotherapy (0% versus 40%; log-rank P=0.002).
Conclusions: Results of the present study suggest a significant reduction in mortality in cancer patients with FN and GI
symptoms treated with combination cefepime-metronidazole therapy compared with monotherapy using agents with
antipseudomonal and anti-anaerobic activity. Further randomized trials are warranted to confirm the superior results
using combination therapy in patients with FN and GI symptoms.
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Febrile neutropenia (FN) induced by cytotoxic chemo-
therapy is known to predispose patients to anaerobic
bacteremia [1]. Damage to the gastrointestinal (GI) mu-
cosa caused by anti-cancer agents provides a portal of
entry for commensal anaerobic bacteria. This fact, in as-
sociation with a decreased host response to infection
due to granulocytopenia and impaired cellular immunity,
may contribute to bloodstream infection caused by bacter-
ial translocation [2]. Despite its low incidence, anaerobic
bacteremia is usually associated with high morbidity and
mortality rates, especially in the context of cancer and im-
munosuppression [3-5].* Correspondence: lgoldani@ufrgs.br
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unless otherwise stated.Timely empirical therapy using an antipseudomonal,
broad-spectrum antibiotic is part of the initial manage-
ment of FN [6,7]. Anti-anaerobic coverage is usually rec-
ommended by guidelines as part of the initial treatment
when GI symptoms (eg, abdominal pain, diarrhea, peri-
anal pain) are present [8,9]. Unfortunately, only scarce
data regarding the optimal anti-anaerobic antimicrobial
strategy for patients with FN and GI symptoms are avail-
able. The aim of the present study was to compare the
mortality rates of hospitalized adult cancer patients with
FN and GI symptoms who either underwent monother-
apy using an antibiotic with antipseudomonal and anti-
anaerobic activity or were treated with a combination of
cefepime and metronidazole.
Study design and participants
A prospective cohort study was conducted in a single
tertiary centre from October 2009 to August 2011. All
consecutive cancer patients admitted to the hematologyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Alegre, Brazil) with neutropenia (absolute neutrophil
count <500 cells/mm3, or <1000 cells/mm3 with an ex-
pectation of a decrease to <500 cells/mm3 during the
ensuing 48 h), fever (a single axillary temperature mea-
surement ≥38.5°C or sustained temperature ≥38.0°C over
a 1 h period) and GI symptoms (abdominal pain, pres-
ence of loose or watery stool, or perianal pain) were eli-
gible for the present study. Subjects who were receiving
only palliative treatment or who had an indication for
outpatient treatment or neutropenia due to a specific
etiology other than an adverse reaction to chemotherapy
were excluded. Patients were not allowed to reenter the
study after a first episode of FN with GI symptoms.
Definitions
The primary independent variable was the initial anti-
microbial treatment administered by the medical care
team. Due to observational study design, the research
team did not influence treatment or diagnostic proce-
dures. Patients were classified into two groups: subjects
who received monotherapy using an antibiotic with anti-
pseudomonal and anti-anaerobic activity (piperacillin-
tazobactam 4.5 g intravenous [IV] over a 4 h period
every 8 h, or imipenem-cilastatin 500 mg IV every 6 h
or meropenem 1 g IV every 8 h); and subjects treated
with a combination of cefepime 2 g IV every 8 h plus
metronidazole 500 mg IV every 8 h. Clinical comorbidity
was defined as the presence of heart failure, diabetes
mellitus, chronic pulmonary disease or chronic liver dis-
ease. Nosocomial-acquired FN was defined as the onset
of FN after 48 hours of hospitalization. High-dose
chemotherapy was defined as induction chemotherapy
or hematopoietic stem cell transplantation. The Multi-
national Association for Supportive Care in Cancer risk
index score [10] was applied at the onset of fever to de-
termine the risk for serious complications during an epi-
sode of FN; episodes were classified as high risk if the
score was < 21 and low risk if the score was ≥ 21. Micro-
biological studies were performed at the onset of fever
according to standards of practice and included two sep-
arate blood samples from two different anatomical sites
for aerobic culture, and enzyme immunoassay testing for
Clostridium difficile toxin A and B in a stool sample
from patients with diarrhea. Antibiotic susceptibilities of
the isolated pathogens were evaluated according to the
recommendations of the Clinical and Laboratory Stan-
dards Institute [11]. Pseudomembranous colitis was di-
agnosed through a positive test for C. difficile toxin in a
stool sample. Neutropenic enterocolitis was defined as
bowel wall thickening >4 mm at the terminal ileus,
cecum or ascending colon documented by abdominal
computed tomography performed in patients who expe-
rienced abdominal pain.Outcome and follow-up
The primary outcome measure of the present study was
mortality 28 days after the onset of FN. Patients were
followed-up through interviews and medical record re-
views using a standardized data collection instrument by
researchers who were not associated with the assistant
physician’s team. Follow-up was maintained for 28 days
after the onset of fever in neutropenic patients. For sub-
jects who were discharged before 28 days, follow-up
telephone calls were made on the 28th day after the on-
set of FN to determine whether they remained alive.
Statistical analysis
The χ2 and Fisher’s exact tests were used to compare
categorical variables; the Mann–Whitney U test was
used to compare continuous variables. Kaplan-Meier
curves were used to calculate the time-dependent occur-
rence of death. The log-rank test was used for compari-
sons between groups. Statistical analysis was performed
using STATA version 12 (Stata Corp LP, USA).
Ethics issues
The Institutional Review Board of the Hospital de Clínicas
de Porto Alegre approved the study and written informed
consent was obtained from all study participants.
Results
In total, 37 patients were evaluated during the study
period; patients with hematological malignancies com-
prised 75% of the study population. The predominant
neoplastic diseases were acute myeloid leukemia (35.1%),
lymphoma (21.6%), acute lymphoblastic leukemia (16.2%)
and multiple myeloma (16.2%). The proportion of patients
who underwent high-dose chemotherapy was 56.7%. Anti-
biotic prophylaxis with fluoroquinolones was not adminis-
tered to any patient. Fifteen subjects initially underwent
monotherapy using an antibiotic with antipseudomonal
and anti-anaerobic activity (12 received piperacillin-
tazobactam; three received a carbapenem), while 22 sub-
jects were initially treated with a combination of cefepime
and metronidazole. The overall mortality rate in the
present cohort was 16.2% (six patients).
Characteristics of the patients who underwent mono-
therapy using an antibiotic with antipseudomonal and
anti-anaerobic activity and those treated with a combin-
ation of cefepime and metronidazole are presented in
Table 1. There were no statistically significant differences
between the two groups with regard to baseline charac-
teristics. The incidence of neutropenic enterocolitis,
pseudomembranous colitis, aerobic bacteremia and
in vitro resistance of aerobic blood isolates to initial anti-
biotic treatment was also similar for the two study arms.
The 28-day mortality rate was significantly lower in
the combination therapy group compared with the
Table 1 Characteristics of patients with febrile neutropenia (FN) and gastrointestinal symptoms





Age, years, mean (SD) 44.7 (14.3) 41.2 (11.0) 0.43
Female sex 15 (68.1) 5 (33.3) 0.05
Type of Cancer 0.18c
Acute myeloid leukemia 6 (27.3) 7 (46.7)
Acute lymphoblastic leukemia 4 (18.2) 2 (13.3)
Chronic myeloid leukemia 1 (4.5) 2 (13.3)
Multiple myeloma 6 (27.3) 0 (0)
Lymphoma 5 (22.7) 3 (20.0)
Other solid tumors 0 (0) 1 (6.7)
Relapsing underlying disease 13 (59.0) 12 (80.0) 0.28
Clinical comorbidity 5 (22.7) 7 (46.6) 0.16
High dose chemotherapy regimens 12 (54.5) 9 (60.0) 0.74
Nosocomial-acquired episode of FN 19 (86.3) 13 (86.6) 0.97
ANC at the time of diagnosis of FN, median cells/mm3 (IQR) 80 (160) 130 (360) 0.47
ANC <100 cells/mm3 at the time of diagnosis of FN 13 (59.0) 6 (40.0) 0.32
High-risk MASCC score 8 (36.3) 2 (13.3) 0.15
Neutropenic enterocolitis 1 (4.5) 1 (6.6) 0.99
Pseudomembranous colitis 1 (4.5) 1 (6.6) 0.99
Documented aerobic bacteremia 8 (36.3) 9 (60.0) 0.19
In vitro resistance of aerobic blood isolates to initial antibiotic treatment 1 (4.5) 2 (13.3) 0.55
Data presented as n (%) unless otherwise indicated. aCefepime + metronidazole; bPiperacillin-tazobactam or imipenem or meropenem; cChi-square test for goodness of
fit; ANC Absolute neutrophil count; HSCT Hematopoietic stem cell transplantation; IQR Interquartile range (P75–P25); MASCC Multinational Association for Supportive
Care in Cancer; SD Standard deviation.
Figure 1 Survival curves according to antibiotic strategy in
patients with febrile neutropenia and gastrointestinal symptoms.
Figure legend: *Combination therapy: cefepime + metronidazole;
†monotherapy: piperacillin-tazobactam or imipenem or meropenem.
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(Figure 1). The assessment of whether mortality was at-
tributable to infection was concordant in all six patients
who died.
Conclusions
The present study demonstrated higher survival rates in
adult cancer patients with FN who presented with GI symp-
toms treated with a combination of a fourth-generation
cephalosporin plus metronidazole compared with those
who underwent monotherapy using a broad-spectrum anti-
biotic with antipseudomonal and anti-anaerobic activity.
The findings of this study have scientific plausibility
given that an antimicrobial strategy using a combination
of cefepime and metronidazole has better coverage for
anaerobic pathogens than a monotherapy strategy
(piperacillin-tazobactan or a carbapenem). This hypoth-
esis is supported by the fact that, in our study, the inci-
dence of aerobic bacteremia and the proportion of
in vitro resistance of aerobic blood isolates to initial anti-
biotic treatment were similar in the two treatment arms.
Moreover, previous efficacy studies involving distinct
populations have reported results convergent with those
obtained in the present cohort. In a randomized clinicaltrial involving 122 patients with intra-abdominal infec-
tions, Garbino et al. [12] reported higher success rates
with combination cefepime-metronidazole treatment
compared with imipenem-cilastatin monotherapy (87%
versus 72%; P=0.004). Similarly, Barie et al. [13] reported
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pime plus metronidazole compared with imipenem-
cilastatin treatment in adult subjects with complicated
intra-abdominal infections (88% versus 76%; P=0.02).
The high impact in risk reduction of mortality found in
our study using combination cefepime-metronidazole
treatment may be due the high levels of characteristically
expected morbidity and mortality of our study popula-
tion, which consisted of a large proportion of high-risk
neutropenic patients in whom the correct choice of anti-
microbial strategy is of paramount importance. In
addition, considering the low incidence of C. difficile col-
itis in both arms of our study, empirical addition of metro-
nidazole to the initial regimen suggests improved efficacy
against anaerobes other than C. difficile in this setting. In
fact, metronidazole has good activity against pathogenic
anaerobic bacteria, and a favourable pharmacokinetic and
pharmacodynamic profile [14]; furthermore, combining
metronidazole with cefepime in patients with FN and GI
symptoms may provide additional advantages over mono-
therapy strategies using piperacillin-tazobactam or carba-
penems because this combination is less expensive and
has a lower potential of inducing antimicrobial resistance,
especially in Gram-negative bacteria.
This study has some limitations, mainly related to the
small study population and to the unicentre observa-
tional design; however, proper measurement of variables
and outcomes with previously defined objective criteria,
use of standardized data collection, as well as follow-up
for research team that was not related to care, mini-
mized the possibility of systematic errors.
Given the scarce data in the literature regarding this
important issue, larger randomized trials are required
to confirm the superiority of combination cefepime-
metronidazole treatment over broad-spectrum mono-
therapies in patients with FN and GI symptoms.
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